Cell-Mediated Immune Response in Patients Undergoing Prostatic Hyperthermia

  • Stanislaw Szmigielski
  • Bronislaw Stawarz
  • Zbigniew Petrovich


The use of hyperthermia (HT) treatment regimes for advanced cancer of the prostate (CaP) and symptomatic benign prostatic hyperplasia (BPH) has now led to the accumulation of considerable clinical experience (Bichler et al. 1992; Perlmutter 1992; Meier et al. 1992), although the mechanisms underlying HT-evoked remissions of prostatic diseases are not known. Most of the HT systems applied at present for the treatment of prostatic disease use various frequencies of microwave (MW) radiation as the source of thermal energy (Perlmutter 1992), with 2450 MHz, 915 MHz, and 434 MHz being most frequently utilized. The MW energy of these frequencies is rapidly absorbed in tissues and effective penetration of 434–2450 MHz MWs to tissues surrounding HT antennas is relatively limited (see Chap. 13). A transurethral (TUHT), 630- or 915-MHz MW applicator described by Astrahan et al. (1989), which wasbuilt of three antennas located in a modified Foley-type catheter, could effectively heat periurethral tissues to a depth of about 0.5–1.0 cm (Chap. 13). When the applicator was installed intraurethrally and the feedback thermoregulation was set at 46°C, a cylindrical volume approximately 4 cm in length and 0.5 cm outward from the catheter was heated from 47°C to 42°C. The temperature gradient was measured as 6°C/cm of prostatic tissue (Astrahan et al. 1991). Similar temperature gradients were registered during transrectal hyperthermia (TRHT) of the prostate with the use of systems and applicators at 2450 MHz (Magin et al. 1980).


Benign Prostatic Hyperplasia Prostatic Tissue Benign Prostatic Hyperplasia Patient Symptomatic Benign Prostatic Hyperplasia Local Hyperthermia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Astrahan M, Sapoznik MD, Cohen D, et al. (1989) Microwave applicator for transurethral hyperthermia of benign prostatic hyperplasia. Int J Hyperthermia 5:283–296CrossRefGoogle Scholar
  2. Astrahan M, Imanaka K, Jozsef G, et al. (1991) Heating characteristics of helical microwave applicator for transurethral hyperthermia of benign prostatic hyperplasia. Int J Hyperthermia 7:141–156PubMedCrossRefGoogle Scholar
  3. Baert L, Willemen P, Ameye F, Petrovich Z (1991) Treatment response with transurethral microwave hyperthermia in different forms of benign prostatic hyperplasia: a preliminary report. Prostate 18:315–320PubMedCrossRefGoogle Scholar
  4. Bichler KH, Strohmaier WL, Wilbert DM (1992) Hyperthermia of the prostate. State of the art. PMI, FrankfurtGoogle Scholar
  5. Catalona WJ, Chritien PB, Trahan EE (1974) Abnormalities of cell-mediated immunocompetence in genitourinary cancer. J Urol 111:229–232PubMedGoogle Scholar
  6. Dumanski Z, Stawarz B, Zielinski H, Szmigielski S (1994) Histologic and ultrastructural changes of the prostate following transrectal and transurethral hyperthermia with 434 MHz or 2450 MHz microwave applicators. Urol Res (in print)Google Scholar
  7. Greeley EH, Helfrich BA, Feuerman LL, et al. (1992) Radiant heat-induced hyperthermia in mice: in vivo effects on the immune system. Int J Hyperthermia 8:209–220PubMedCrossRefGoogle Scholar
  8. Herr HW (1980) Suppressor cell in immunodepressed bladder and prostate cancer patients. J Urol 123:635–639PubMedGoogle Scholar
  9. Izumi A, Koga S, Maeta M (1983) Effects of in vitro hyperthermia on murine and human lymphocytes. Cancer 51:2061–2065PubMedCrossRefGoogle Scholar
  10. Kastelan M, Kraljic I, Tarle M (1992) NK cell activity in treated cancer prostate patients as a sensitive probe for circulating tumor cells: hormone regulatory effects in vivo. Prostate 21:111–119PubMedCrossRefGoogle Scholar
  11. Lahat N, Alexander N, Levin DR, Moskovitz B (1989) The relationship between clinical stage, natural killer activity and related immunological parameters in adenocarcinoma of the prostate. Cancer Immunol Immunother 28:208–215PubMedCrossRefGoogle Scholar
  12. Lauweryns J, Baert L, Vandenhove J, Petrovich Z (1991) Histopathology of prostatic tissue after transurethral hyperthermia. Int J Hyperthermia 7:221–230PubMedCrossRefGoogle Scholar
  13. Leib Z, Rathem A, Lev A, Servadio C (1986) Histopathological observations in the canine prostate treated by local microwave hyperthermia. Prostate 8:93–102PubMedCrossRefGoogle Scholar
  14. Magin RL, Fridd CW, Bonfiglio TA (1980) Thermal destruction of the canine prostate by high intensity microwaves. J Surg Res 29:265–275PubMedCrossRefGoogle Scholar
  15. Mandeville R, Lamoureux G, Legault-Poisson S, Poisson R (1982) Biological markers and breast cancer. A multiparametric study. II. Depressed immune competence. Cancer 50:1280–1288PubMedCrossRefGoogle Scholar
  16. Meier AHP, Weil EHJ, Van Waalwijk ESC, Verhaegh GTCM, Janknegt RA (1992) Transurethral radiofrequency heating or thermotherapy for benign prostatic hypertrophy: a prospective trial on 65 consecutive cases. Eur Urol 22:39–43PubMedGoogle Scholar
  17. Montrosi F, Galli L, Guazzoni G, et al. (1992) Transrectal microwave hyperthermia for benign prostatic hyperplasia: long-term clinical, pathological and ultrastructural patterns. J Urol 148:321–325Google Scholar
  18. Perlmutter AP (1992) Prostatic heat treatments. Semin Urol 10:169–179PubMedGoogle Scholar
  19. Robins HI, Jonsson GG, Jacobson EL, et al. (1991) effect of hyperthermia in vitro and in vivo on adenine and pyridine nucleotide pools in human peripheral lymphocytes. Cancer 67:2096–2102Google Scholar
  20. Servadio C, Leib Z, Lev A (1986) Further observations on the use of local hyperthermia for the treatment of diseases of the prostate. Eur 12:38–40Google Scholar
  21. Servadio C, Leib Z, Lev A (1987) Diseases of the prostate heated by local microwave hyperthermia. Urology 30:97–99PubMedCrossRefGoogle Scholar
  22. Servadio C, Leib Z, Lev A (1990) Local hyperthermia to canine prostate. A pilot study. Urology 35:156–164PubMedCrossRefGoogle Scholar
  23. Sobczynski J, Szmigielski S, Stawarz B, Zielinski H, Ogrodnik J (1994) Reaction of granulocyte system and changes in lymphocyte function in patients treated with microwave hyperthermia for prostate cancer and benign prostatic hyperplasia. Eur Urol (in print)Google Scholar
  24. Stawarz B, Szmigielski S, Ogrodnik J, Petrovich Z (1991) A comparison of transurethral and transrectal microwave hyperthermia in poor surgical risk BPH patients. J Urol 146:353–357PubMedGoogle Scholar
  25. Stawarz B, Zielinski H, Szmigielski S, et al. (1993) Transrectal hyperthermia as a palliative treatment for advanced adenocarcinoma of the prostate and a study of cell mediated immunity. Urology 41:548–553PubMedCrossRefGoogle Scholar
  26. Strohmaier WL, Bichler KH, Fluchter SH, Wilbert DM (1992) Local microwave hyperthermia of benign prostatic hyperplasia. J Urol 144:913–917Google Scholar
  27. Szmigielski S, Zaboklicki S, Gil J, Jeljaszewicz J, Pulverer G (1984) Inhibition of Lewis lung carcinoma in mice by local microwave hyperthermia combined with immunomodulating Propionibacterium granulosum KP-45. Cancer Immunol Immunother 16:151–159PubMedCrossRefGoogle Scholar
  28. Szmigielski S, Jeljaszewicz J, Pulverer G (1987) Thermoimmunotherapy of advanced neoplasms. A concept and preliminary results. Biomed Pharmacother 18:132–141Google Scholar
  29. Szmigielski S, Stawarz B, Zielinski H, Gil J, Sobczynski J, Sokolska G, Jeljaszewicz J, Pulverer G (1988) Local microwave hyperthermia in the treatment of advanced prostatic adenocarcinoma. Urol Res 16:1–7PubMedCrossRefGoogle Scholar
  30. Szmigielski S, Sobczynski J, Sokolska G, Stawarz B, Zielinski H, Petrovich Z (1991) Effects of local prostatic hyperthermia on human NK and T cell function. Int J Hyperthermia 7:869–880CrossRefGoogle Scholar
  31. Tarle M, Kraljic I, Kastelan M (1993) Comparison between NK cell activity and prostate cancer stage and grade in untreated patients: correlation with tumor markers and hormonal serotest data. Urol Res 21:17–21PubMedCrossRefGoogle Scholar
  32. White D, Jones DB, Cooke T, Kirkham N (1982) Natural killer (NK) activity in peripheral blood lymphocytes of patients with benign and malignant breast disease. Br J Cancer 46:611–616PubMedCrossRefGoogle Scholar
  33. Yang H, Lauzon W, Lemaire I (1992) Effect of hyperthermia on natural killer cells: inhibition of lytic function and microtubule organization. Int J Hyperthermia 8:87–97PubMedCrossRefGoogle Scholar
  34. Yerushalmi A, Servadio C, Leib Z, Fishelovitz Y, Rokovsky E, Stein J (1982) Local hyperthermia for treatment of carcinoma of the prostate. Prostate 6:623–630CrossRefGoogle Scholar
  35. Yoshioka A, Miyachi Y, Toda K, Imamura S, Hiraoka M, Abe M (1990) Effects of local hyperthermia on natural killer activity in mice. Int J Hyperthermia 6:261–267PubMedCrossRefGoogle Scholar
  36. Zembala M, Mytar B, Popiela T, Asherson GL (1977) Depressed in vitro peripheral blood lymphocyte response to mitogens in cancer patients: the role of suppressor cells. Int J Cancer 19:605–613PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • Stanislaw Szmigielski
    • 1
  • Bronislaw Stawarz
    • 2
  • Zbigniew Petrovich
    • 3
  1. 1.Center for Radiobiology and Radiation SafetyMMA Postgraduate, Medical SchoolWarsawPoland
  2. 2.Department of UrologyMMA Postgraduate, Medical SchoolWarsawPoland
  3. 3.Department of Radiation Oncology, Kenneth Norris Jr. Cancer CenterUniversity of Southern CaliforniaLos AngelesUSA

Personalised recommendations